Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227116 | 1.00 | CHRM2 (0.55) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL227055 | 0.87 | CHRNA7 (0.60) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL227054 | 0.87 | CHRNA7 (0.60) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL227223 | 0.85 | CHRM3 (0.62) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL227222 | 0.85 | CHRM3 (0.62) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL15335456 | 0.82 | CHRM2 (0.57) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL3219330 | 0.79 | MEN1 (0.51) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL3219324 | 0.79 | MEN1 (0.51) | CHRM2CHRM3CHRM1CHRM4CHRM5 | |
| SCHEMBL229454 | 0.78 | CHRNA7 (0.49) | CHRM2CHRM3CHRM1CYP2D6CHRNA7 | |
| SCHEMBL229455 | 0.78 | CHRNA7 (0.49) | CHRM2CHRM3CHRM1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313404-B1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMA SPA (IT) | 2012-03-28 | — | — | EP | disclosed |
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-01-05 | — | — | US | disclosed |
| US-8039483-B2 | Quinuclidine carbonate salts and medicinal composition thereof | CHIESI FARMACEUTICI S.P.A. (IT) | 2011-10-18 | — | — | US | disclosed |
| EP-2313404-A1 | QUINUCLIDINE CARBONATE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004258-A1 | QUINUCLIDINE CARBONATE SALTS AND MEDICINAL COMPOSITION THEREOF | CHRM3, CHRM2, CHRM4 | CHRM2 2/4885CHRM3 1/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.